Companies · A
Agilent Technologies
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Sep 1, 2026
Agilent Q3 FY2026: Broad-Based 8% Revenue Growth With Biocare Acquisition Expanding Pathology Portfolio and Tariff Refunds Lifting Margins
Agilent delivered 8% revenue growth in Q3 FY2026 across all three segments and all geographies, with the Life Sciences and Diagnostics Markets segment leading at 11% growth in the quarter, driven by pharma, diagnostics, and the newly acquired Biocare pathology business. Operating margin expanded 3 percentage points to 23.6% in Q3, with approximately 1 percentage point of that improvement attributable to IEEPA tariff refunds recognized under the gain contingency model. The $950 million acquisition of Biocare — funded partly by $600 million in new 2032 senior notes — represents Agilent's most consequential single-quarter strategic action, extending its pathology reach into clinical settings immediately ahead of what management describes as a normalized customer capital spending environment.
Tone: bullishRevenue
$6.9B
A 10-K · FY 2025
Employees
18,100
Revenue growth YoY
+7%
Founded
1999
Profile
A 10-K Item 1 · Dec 22, 2025Agilent Technologies is a global provider of analytical instruments, software, services and consumables serving life sciences, diagnostics and applied markets. The company operates through three segments — Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets — each targeting distinct laboratory workflow needs. Its customer base spans pharmaceutical and biopharmaceutical companies, clinical and academic institutions, food and environmental testing labs, and advanced materials manufacturers.
Read filing description ↓ Collapse description ↑
Agilent Technologies, Inc., incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. In November 2024, Agilent announced a change in its organizational structure to support its market-focused, customer-centric strategy. The former Diagnostics and Genomics segment combined with liquid chromatography and liquid chromatography mass spectrometry instrument platforms to form the new Life Sciences and Diagnostics Markets segment. Chemistries and supplies, laboratory automation, and software and informatics divisions moved from the former Life Sciences and Applied Markets segment to the Agilent CrossLab segment. The remaining divisions — gas chromatography, gas chromatography mass spectrometry, remarketed instruments, spectroscopy and vacuum — formed the new Applied Markets segment. The Life Sciences and Diagnostics Markets segment provides specialty contract development and manufacturing services for pharmaceutical customers, as well as reagents, instruments, software and consumables enabling cellular and molecular analysis. The Agilent CrossLab segment spans the entire lab with an extensive services and consumables portfolio, plus software and laboratory automation solutions. The Applied Markets segment provides application-focused solutions enabling customers to identify, quantify and analyze the physical and biological properties of substances and products. Products are sold primarily through direct sales, with supplementary channels including distributors, resellers, manufacturers' representatives and electronic commerce. Primary research and development and manufacturing sites span the U.S., Australia, Canada, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore and the United Kingdom.
Primary products
- Liquid chromatography systems and components
- Liquid chromatography mass spectrometry systems
- Gas chromatography systems
- Gas chromatography mass spectrometry systems
- Pathology solutions
- Cell analysis platforms
Business segments
End markets
Geographies
Named customers
Named competitors
“We compete on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Total net revenue increased 7 percent in fiscal year 2025 compared to fiscal year 2024, with growth contributions from all three segments, all geographic regions, and most key end markets, including approximately 2 percentage points from the BIOVECTRA acquisition.
The rest of A is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.